Island Pharmaceuticals Ltd (AU:ILA) has released an update.
Island Pharmaceuticals Ltd has initiated patient screening for the Phase 2 PROTECT study of ISLA-101, their antiviral drug for dengue fever, after receiving U.S. Army Institutional Review Board approval. The clinical trial, which includes both preventative and treatment arms, is set to commence dosing in late September with full trial results expected by the end of 2024. This development positions Island well in the race to address the urgent need for dengue therapeutics.
For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.
